ADORA2A and renal cell carcinoma: The A2aR antagonist ciforadenant has shown therapeutic activity and good tolerance in patients receiving immunotherapy for the first time and in patients resistant or refractory to anti-PD-1/L1 treatment in a phase 1 clinical trial in renal cell carcinoma (22).